1. In Vivo
  2. >>Business Strategy

Epigenomics Gets What Companies Rarely Do: A Huge Deal

Roche Diagnostics and Epigenomics AG, a start-up diagnostics company, have signed a three-year collaboration to find new cancer diagnostic markers, a deal that could bring Epigenomics as much as $100 million--if all of the markers covered get to market. Epigenomics is working on DNA methylation based biomarkers for cancer and will identify the markers; Roche will develop them into tests and market them worldwide.

The new three-year collaboration between Roche Diagnostics (a division of Roche ) and start-up company Epigenomics AG [See Deal] is striking both because of its value—as an alliance one of the highest-valued deals signed in recent years--and because of the faith it places in DNA methylation technology, which has long been under investigation and is now in the spotlight. (See "Epigenomics GMBH," START-UP, February 2000 Also see "Epigenomics GMBH" - Medtech Insight, 1 February, 2000..)

For many small diagnostics companies, the deal is an enviable model of the kind they would like to achieve with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Dealmaking Quarterly Statistics, Q2 2025

 
• By Maureen Riordan and Deanna Kamienski

During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.

Infographic: How Big Pharma Is Scaling Beyond Pilot AI Projects

 
• By David Wild

Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.

When VC Steps Back: Finding Alternative Biotech Funding

 
• By Jo Shorthouse

The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 
• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

More from In Vivo

PBMs Tighten The Reins: Value Becomes The New Access Gatekeeper

 
• By Andrew Cox

Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.

Akelos’ Peripheral HCN1 Blocker Looks To End Opioid Dependence In Neuropathic Pain

 
• By Jo Shorthouse

Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.

Future Proofing Gene Therapy Assays For Regulatory Success

 
• By Deborah Phippard

As gene therapy advances and regulations tighten, biopharma companies face growing pressure to design diagnostic assays that are both flexible and future ready. Strategic early investment in assay development can prevent costly delays and rework as therapies progress toward approval.